









DB 490 TTAGGCAAGAGGCGAAGCACTTTGGAGGCTATGATCTGTAAGTGTGATATAAAGGCTTCGAT 549  
QY  
DB 860 TTATGATATATGAGGCAAAATATCAATGCTATGATATAGAGCAAAATGCTGCTGGTACG 919  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 559 CTCACTATATTTGGAGCTAAATATCAATGCTATGATATAGAGCAAAATGCTGCTGGTACG 609  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 920 TATCAGTGTAGCAGCTTTCTGCTGATGTTATACCTATATATGAGTATATGAGTGTAAATGT 979  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 610 TATCAGTGTAGCAGCTTTCTGCTGATGTTATACCTATATATGAGTATATGAGTGTAAATGT 669  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 980 AAAAGAGATATACAGAGTATGATGCTGATGCTGATGCTGATGCTGATGCTGATGCTGATGCTG 1039  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 670 AAAAGAGATATACAGAGTATGATGCTGATGCTGATGCTGATGCTGATGCTGATGCTGATGCTG 729  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1040 CTTCAAGTGTCAATTCATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1099  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 730 CTTCAAGTGTCAATTCATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 789  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1100 AATAAATATGATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1159  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 790 AATAAATATGATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 849  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1160 CTTCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1219  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 850 CTTCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 909  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1220 ATACCAATTCCTATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1279  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 910 ATACCAATTCCTATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 969  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1280 CTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1339  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 970 CTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1029  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1340 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1399  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1030 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1089  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1400 GATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1459  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1090 GATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1149  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1460 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1519  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1150 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1209  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1520 AATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1579  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1210 AATTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1269  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1580 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1639  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1270 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1329  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1640 GATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1699  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1330 GATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1389  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1700 CTGCTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1759  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1390 CTGCTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1449  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1760 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1819  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1450 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1509  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1820 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1879  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1510 ATACCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1569  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
QY 1880 CTGCTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1939  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1570 CTGCTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1629  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT

QY 1940 GAAAGAAAG 1948  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
DB 1640 GAAAGAAAG 1636  
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  
RESULT 4  
AAAG52268  
ID AAAG52268 standard; DNA; 3003 BP.  
XX  
AC AAAG52268;  
XX  
DT 25 JUN 1999 (first entry)  
XX  
DE Protein BR0334 cDNA clone DNA41379-1236.  
XX  
KW Secreted protein; transmembrane protein; human; enterocolitis;  
KW Zollinger-Ellison syndrome; gastrointestinal ulceration;  
KW congenital microvillus atrophy; skin disease; cell growth;  
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
KW parkinson's disease; Alzheimer's disease; ALS; neuropathy;  
KW fibromyalgia; dermal scarring; Usher Syndrome; Atrophid areata;  
KW anti-thrombotic; wound healing; tissue repair; ss.  
CS Homo sapiens.  
XX  
PN W09414428-A2.  
XX  
PD 25 MAR 1999.  
XX  
PF 16 SEP 1998; 98W-UST19430.  
XX  
PR 25 NOV 1997; 97US-0066840.  
PR 17 SEP 1997; 97US-0059114.  
PR 17 SEP 1997; 97US-0059115.  
PR 17 SEP 1997; 97US-0059117.  
PR 17 SEP 1997; 97US-0059119.  
PR 17 SEP 1997; 97US-0059121.  
PR 17 SEP 1997; 97US-0059122.  
PR 17 SEP 1997; 97US-0059184.  
PR 18 SEP 1997; 97US-0059203.  
PR 18 SEP 1997; 97US-0059206.  
PR 18 SEP 1997; 97US-0062125.  
PR 17 SEP 1997; 97US-0062285.  
PR 17 SEP 1997; 97US-0062287.  
PR 21 SEP 1997; 97US-0063386.  
PR 24 SEP 1997; 97US-0062814.  
PR 24 SEP 1997; 97US-0062816.  
PR 24 SEP 1997; 97US-0063045.  
PR 24 SEP 1997; 97US-0063120.  
PR 24 SEP 1997; 97US-0063121.  
PR 24 SEP 1997; 97US-0063127.  
PR 24 SEP 1997; 97US-0063128.  
PR 27 SEP 1997; 97US-0063329.  
PR 27 SEP 1997; 97US-0063327.  
PR 28 SEP 1997; 97US-0063511.  
PR 28 SEP 1997; 97US-0063542.  
PR 28 SEP 1997; 97US-0063544.  
PR 28 SEP 1997; 97US-0063549.  
PR 28 SEP 1997; 97US-0063550.  
PR 28 SEP 1997; 97US-0063564.  
PR 29 SEP 1997; 97US-0063565.  
PR 29 SEP 1997; 97US-0063704.  
PR 29 SEP 1997; 97US-0063742.  
PR 29 SEP 1997; 97US-0063748.  
PR 29 SEP 1997; 97US-0063744.  
PR 29 SEP 1997; 97US-0064215.  
PR 29 SEP 1997; 97US-0064735.  
PR 31 SEP 1997; 97US-0064870.  
PR 31 SEP 1997; 97US-0064133.  
PR 05 NOV 1997; 97US-0064248.  
PR 07 NOV 1997; 97US-0064809.  
PR 12 NOV 1997; 97US-0065180.











DB		1424	CAGTGAATGTACTGGAAACCAATCAGGAGCAATCAAGGTGGAAATAATCTGGAAATCTGTC	1489
QY		1621	GCGAGCCAAAATCCAGAGGAAAAAGTTGACGCTTGCTGGTAGCTCTGAGGAGGAGCTTAA	1686
DB		1483	GCGAGCCAAAATCCAGAGGAAAAAGTTGACGCTTGCTGGTAGCTCTGAGGAGGAGCTTAA	1542
QY		1681	GTATTACAGGAGGACTGCTGCTGCTCATTCACAGCACAAAGTGTAGAAGGAGTGTGATCTCTAG	1740
DB		1543	GCAATTCAGAGGAGCTGCTGCTGCTCATTCACAGCACAAAGTGTAGAAGGAGTGTGATCTCTAG	1602
QY		1741	AATTCAGAGGCTTTTGTCGACAAACAAGAGTGGTCAAGGAGGAGGAGTGTGATCTCTAG	1800
DB		1603	ATTCAGAGGCTTTTGTCGACAAACAAGAGTGGTCAAGGAGGAGGAGTGTGATCTCTAG	1662
QY		1801	TGGTCAAGCTTGAGAGCAAAATACATATATCTTGGAGGAGGCTGTATATCAAAGGAG	1856
DB		1663	TGGTCAAGCTTGAGAGCAAAATACATATATCTTGGAGGAGGCTGTATATCAAAGGAG	1718
RESULT 7				
AAF74447		10	AAF74447 standard; cDNA; 601 bp.	
XX		AC	AAF74447;	
XX		09 MAY-2001	(first entry)	
XX		Human Pso16 nucleotide sequence SEQ ID NO:31.		
DE		Human; PsoX; cytotastatic immunomodulatory; reproductive;		
KW		gene therapy; cell proliferation; differentiation disorder; cancer;		
KW		immune associated disorder; gestational disease; proclampsia; ss.		
XX		Bone Sapiens.		
XX		WU20110602 AJ.		
FN		15-FEB-2001.		
XX		11 AUG-2000; 2000WUSZ1857		
PF		11 AUG-1999; 990US 0148144.		
PR		10-AUG-2000; 2000US 0148144.		
XX		(CIPA ) CUBAGEN CORP.		
XX		Shunkel's RA, Fernandes E;		
XX		WFO; 2001 34769/15.		
PR		for PSOs, AAB/0546.		
XX				
PT		Nucleic acids encoding secreted polypeptides, designated Pso X		
P1		polypeptides, useful for treating a syndrome associated with a		
P1		PsoX-associated disorder, e.g., cancer		
PS		claim 8; Page 54; 16pp; English.		
XX		The present invention describes isolated nucleic acids encoding secreted		
OC		polypeptides, designated PsoX polypeptides (e.g., a polypeptide where		
OC		X is an integer from 1 to 17). PsoX polypeptides have cytostatic,		
OC		immunomodulatory and reproduction activities, and can be used in gene		
OC		therapy, and as PsoX antagonists and PsoX agonists. PsoX polypeptides,		
OC		nucleic acids and antibodies are useful in the management of a		
OC		dysorder for treating a syndrome associated with a PsoX-associated		
OC		disorder, e.g., cell proliferation and/or differentiation disorder		
OC		(e.g., cancer or immune associated disorders) and a gestational disease		
OC		(e.g., pre-clampsia), they are also used for screening for a modulation of		
OC		activity or of latency or predisposition to a PsoX-associated disorder.		
OC		AAF74442 to AAF74448 encode the specifically claimed human Pso X		
XX		polypeptides Pso17 through to AAF7051 to AAF6042.		
XX		Sequence: 601 bp; 150 A; 200 G; 210 C; 199 T; 6 other(s).		

[illegible]

XX 41-MAR-1999; 990S-0127607.  
 PR 02-APR-1999; 990S-0127636.  
 PR 05-APR-1999; 990S-0127728.  
 PR 40-MAR-2000; 20000S-0540763.  
 XX  
 DA (CHRA ) CHRA GEN CORP.  
 XX  
 XX Shinketsu RA, Leach M;  
 XX  
 XX WPI: 2090-602462/57.  
 DB P-PSDB: AA642085.  
 XX  
 PI Novel nucleic acids and peptides derived from open reading frame X,  
 PI useful for treating e.g. cancers, proliferative disorders,  
 PI neurodegenerative disorders and cardiovascular disease -  
 XX  
 XX Claim 5; Page 2849; 5507pp; English.  
 XX  
 CC AAC74446 to AAC77606 encode the proteins given in AA040237 to AA043397,  
 CC which represent the human OREX open reading frames 1 to 3161. The OREX  
 CC sequences have activities such as: cytostatic; hepatotropic; vulnerary;  
 CC antiproliferative; antiparkinsonian; neurotropic; neuroprotective;  
 CC osteoprotective; anticonvulsant; antirheumatic; immunosuppressant;  
 CC immunostimulant; cardiac; thrombolytic; coagulant; vasotropic;  
 CC antididiabetic; hypotensive; dermatological; immunosuppressive;  
 CC antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;  
 CC antithyroid; and antianemic. The sequences can be used for determining  
 CC the presence of or predisposition to, or preventing or treating  
 CC pathological conditions associated with an OREX associated disorder. The  
 CC nucleic acids can be used to express OREX proteins in gene therapy  
 CC vectors. The proteins and nucleic acids may be used to treat cancers,  
 CC proliferative disorders, neurodegenerative disorders, osteoarthritis,  
 CC graft vs host disease, cardiovascular disease, diabetes mellitus,  
 CC hypertension, hypothyroidism, cholesterol ester storage, systemic lupus  
 CC erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,  
 CC bacterial or fungal infection, malaria, autoimmune disorders, asthma,  
 CC allergies, aplastic anemia, burns, wounds, bone and cartilage damage,  
 CC neuronal haemoglobinuria, antinflammatory disease; to enhance  
 CC coagulation; to inhibit thrombolysis; and as a contraceptive.  
 XX  
 SQ Sequence 550 BP; 127 A; 130 C; 160 G; 132 T; 1 other;

Query Match 22.78; Score 480; BB 21; Length 550;

Best Local Similarity 90.79; Pred. No. 1,40-111;

Matches 544; Conservative 0; Mismatches 5; Indels 51; Gaps 1;

QY 252 CGGCGAGCGAGTTTCAGCGGAGGTGGGGGAGCAAAATAGTCATGCGATGGCGATGTC 311

DB 2 CGGCGGCGGAGTTTCAGCGGAGGTGGGGGAGCAAAATAGTCATGCGATGCGATGTC 61

QY 312 GTTATGGTGGGAGGATTGACTGCTGCTGGGGCTGGGGCTGGGCTGGGCTGGGCTGGG 371

DB 312 GTTATGGTGGGAGGATTGACTGCTGCTGGGGCTGGGGCTGGGCTGGGCTGGGCTGGG 121

QY 372 AGCTTTCTACGCTTFAAGGAGAGGAAATAGCAAGGATAAGGATAGGTTTAAAGTAA 431

DB 372 AGCTTTCTACGCTTFAAGGAGAGGAAATAGCAAGGATAAGGATAGGTTTAAAGTAA 130

QY 432 GTCAGATGAGAAATGAAATGATGATGAGGATGAAATGAAATGAAATGAAATGAAATG 491

DB 432 GTCAGATGAGAAATGAAATGATGATGAGGATGAAATGAAATGAAATGAAATGAAATG 190

QY 492 GTTATGCTGGGAAAGCTTGTATTAAGTTTAAATGAGGCTGGGCTGGGCTGGGCTGGG 551

DB 492 GTTATGCTGGGAAAGCTTGTATTAAGTTTAAATGAGGCTGGGCTGGGCTGGGCTGGG 250

QY 552 GTAAATGAGGCTGATGAGCACTTAAATGAGGCTGATGAGGCTGATGAGGCTGATGAG 611

DB 552 GTAAATGAGGCTGATGAGCACTTAAATGAGGCTGATGAGGCTGATGAGGCTGATGAG 310

QY 612 TGTATGAGGCTGATGAGCACTTAAATGAGGCTGATGAGGCTGATGAGGCTGATGAG 671

DB 612 TGTATGAGGCTGATGAGCACTTAAATGAGGCTGATGAGGCTGATGAGGCTGATGAG 1

DB 311 TGTATGAGGCTGATGAGCACTTAAATGAGGCTGATGAGGCTGATGAGGCTGATGAG 531

QY 672 ATGGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 741

DB 672 ATGGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 440

QY 742 TGGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 791

DB 742 TGGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 490

QY 792 TGGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 851

DB 792 TGGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 550

RESULT 9

AAL22819

DB AAL22819 standard; cDNA; 690 BP.

XX AAL22819;

XX 07-DEC-2001 (first entry)

XX Human breast cancer expressed polynucleotide 15276.

XX Human breast cancer; cell marker; cytostatic; SS.

XX Homo sapiens.

XX WU-2001-51628-A2.

DB 19-JUL-2001.

XX 10-JAN-2001; 2001WU-US00798.

XX 14-JAN-2000; 2000US-0176477.

XX 14-MAR-2000; 2000US-0189167.

XX 24-MAR-2000; 2000US-0192099.

XX 29-MAR-2000; 2000US-0193480.

XX 15-MAY-2000; 2000US-0205240.

XX 09-JUN-2000; 2000US-0211415.

XX 25-JUN-2000; 2000US-0220544.

XX (MILL ) MILLENNIUM PREDICTIVE MEDICINE INC.

XX L.Hille J, Xu Y, Waud Y, Steinmann K;

XX WPI: 2001-451855/48.

XX New peptide useful as a marker for the diagnosis of breast cancer -

XX Claim 1; Page 2767; 4695pp; English.

XX The invention relates to human breast cancer expressed polynucleotides

XX (AAL27544-AAL2789) and methods of assessing whether a patient is

XX afflicted with breast cancer by examining the correlation between the

XX expression of certain markers and the cancerous state of breast cells.

XX The polynucleotides and encoded polypeptides are potential markers for

XX detecting, diagnosing, monitoring, characterizing, treating and

XX potentially preventing breast cancer. The polynucleotides and encoded

XX polypeptides are also useful for isolating compounds with cytostatic

XX activity.

XX Sequence 690 BP; 167 A; 154 C; 182 G; 186 T; 2 other;

XX Query Match 19.99; Score 419.6; BB 22; Length 690;

XX Best Local Similarity 98.94; Pred. No. 3,42-96;

XX Matches 433; Conservative 0; Mismatches 4; Indels 1; Gaps 1;

QY 1676 GTTATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1745

DB 1676 GTTATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1



[illegible]

[illegible][illegible]

[illegible]

